INTRODUCTION
============

PTKs are involved in many cell signaling pathways. These enzymes represent early key regulators in such functions as cell growth, proliferation, differentiation, secretion, and apoptosis \[[@R1]\]. Aberrant protein kinase expression or function is a cause or consequence of many human diseases like cancer and atherosclerosis. As a result, kinases represent very important targets in the development of therapeutics.

Protein kinase selectivity is critical for appropriate intracellular signaling. Kinase-substrate interactions are mediated *via*specific interaction sites such as SH2 domains, but also by the distinct specificity of the catalytic domain. The use of small peptides to investigate kinase specificity and catalysis is supported by crystallographic structures of kinase-peptide complexes as well as studies with synthetic peptide libraries \[[@R2],[@R3]\]. Considering that almost all human PTKs have recently become available as purified recombinant enzymes, it has become possible to profile peptide substrate activity throughout the entire group to possibly reveal novel specificities of individual kinases and kinase sub-families. Previously, a study was performed on the yeast kinome \[[@R4]\] in which nearly all (119) of the yeast protein kinases were overexpressed and assayed in a high-throughput manner on 17 chip-immobilized protein and peptide substrates. However, such an extensive investigation has not been performed with human PTKs.

In this study, three different peptides previously characterized with a small subset of PTK(s) were chosen for screening 81 human PTKs. The three peptides are derived from *bona fide* kinase substrate sequences and therefore represent putative *in vivo* targets. The CDK1 (Tyr15) or p34^cdc2^ (Tyr15) peptide was originally shown to be a suitable substrate for four Src kinases: SRC, LYN, LCK, and FYN \[[@R5]\]. The IRS1 (Tyr983) peptide was chosen to represent a YMXM peptide. Peptides containing the YMXM motif were shown as effective substrates for receptor tyrosine kinases such as the insulin receptor \[[@R6]\], and also for non-receptor Tyr kinases \[[@R7]\]. Finally, the JAK1 (Tyr1023) peptide was shown to be a substrate for JAK3 \[[@R8]\]. In addition to the small peptides, the generic PTK substrates polyGT and polyGAT \[[@R9]\] were tested as controls of PTK activity.

The high-throughput TR-FRET platform, LANCE^®^ *Ultra,* was used to measure enzyme activity, whereby the phosphopeptide product is detected by a highly sensitive anti-pTyr antibody labeled with europium chelate (Fig. **[1](#F1){ref-type="fig"}**). TR-FRET occurs between the chelate-labeled antibody and the dye-conjugated phosphopeptide upon excitation at 320 or 34 nm.

Apart from providing valuable activity data for the 81 PTKs, the profiling experiments demonstrated that the CDK1 and IRS1 peptides are highly selective for certain kinase sub-families, whereas the polyGT, polyGAT, and JAK1 peptides are promiscuous. Furthermore, novel activities for certain kinases, such as the Eph family, have been observed.

MATERIALS AND METHODS
=====================

Materials
---------

All peptides are available from PerkinElmer. The CDK1, IRS1, and JAK1 peptides are labeled with the small fluorescent dye U*Light*^TM^ *via*conjugation to an N-terminal Cys residue, whereas the polyGAT and polyGT are labeled *via*conjugation to the amino terminus of the polypeptides. U*Light*-polyGT (4:1) and U*Light*-polyGAT (1:1:1) are polymers of amino acids (20-50 kDa) in which the amino acid ratios are as indicated. U*Light*-CDK1 (Tyr15) has the sequence: CAGAGKIGEGTYGVVYK; U*Light*-IRS1 (Tyr983): CKKSRGDYMTMQIG; and U*Light*-JAK1 (Tyr1023): CAGAGAIETDKEYYTVKD. The biotinylated pTyr-peptide has the sequence: biotin-AGAGIGEGT (pY)GVVYK. Europium-anti-pTyr (PT66) Antibody was from PerkinElmer. All kinases were recombinant (human origin) and purchased from Carna Biosciences.

Methods
-------

The assays were performed in white, opaque OptiPlate^TM^-384 microplates from PerkinElmer. The kinase reaction buffer consisted of 50 mM HEPES pH 7.5, 1 mM EGTA, 10 mM MgCl~2~, 2 mM DTT and 0.01% Tween-20. EDTA, for stopping the reaction, and the detection antibody were prepared in LANCE Detection Buffer (PerkinElmer). All assay incubations were performed at 23°C and the microplates were sealed with TopSeal-A^TM^ film (PerkinElmer) during that time. The fluorescence signals were read using an excitation filter of 320 nm and an emission filter of 665 nm on an EnVision^®^ Multilabel Reader (PerkinElmer). The final assay volume was 20 µL.

For determination of kinase concentrations to use in the assays that would not interfere in detection by the anti-phospho-Tyr (PT66) antibody, 0 to 30 nM of each kinase was incubated with 50 nM of biotinylated pTyr-peptide in the presence of 200 µM ATP for 2 h. The reaction was stopped by adding 10 mM EDTA and 50 nM U*Light*-Streptavidin for 5 min. 2 nM Europium-anti-pTyr (PT66) antibody was added and incubated for another 1 h before reading the fluorescence.

For kinase profiling, the kinase was incubated with 50 nM (U*Light*-CDK1 and U*Light*-JAK1) or 100 nM (U*Light*-IRS1, U*Light*-polyGT and U*Light*-polyGAT) substrate in the presence or absence of 200 µM ATP. The enzyme reaction proceeded for 2 h before stopping with 10 mM EDTA for 5 min. 2 nM Europium-anti-pTyr antibody was added and incubated for another 1 h before reading the fluorescence. The S/B ratio was calculated by dividing the fluorescence signal of the reaction with ATP by the signal from the reaction without ATP. All reactions were performed in duplicate and the average S/B ratio is reported. Almost all of the individual duplicate values for the S/B ratios were within 15% of the average values.

RESULTS
=======

Determination of the Concentration of Kinase to Use in the Assays
-----------------------------------------------------------------

The pTyr residues in the phosphopeptide products are detected by a highly specific anti-pTyr antibody. This antibody is highly promiscuous, since it is not specific for the peptide sequence surrounding the phosphorylated residue. In some cases, the kinase being analyzed contains Tyr auto-phosphorylation sites. Therefore, the pTyr residues on the kinase can compete for the binding of the antibody to the phosphopeptide product. Hence, the kinase concentration has to be low enough so that it does not interfere with the signal generation. To determine the concentration of kinase to use in the assay, tests with the kinase and a pre-phosphorylated peptide were performed. Sufficient ATP was added to allow for protein autophosphorylation. The fluorescence signal generated by the phosphorylated peptide was plotted versus the concentration of enzyme and an example plot for JAK2 kinase is illustrated in Fig. (**[2](#F2){ref-type="fig"}**). In this case, 1 nM of enzyme was chosen for substrate profiling since the signal begins to decrease at 1 nM of enzyme. For all the kinases, the highest concentration of enzyme providing no significant interference was chosen for determination of activity versus the various U*Light*-substrates. In a few cases, no interference was observed and 20 nM enzyme was used for the reaction.

Kinase Profiling
----------------

81 human PTKs, plus two mutant kinases, Abl (T315I) and EGFR (T790M), were tested against the five substrates and the results are detailed in Table **[1](#T1){ref-type="table"}**. The enzyme concentrations used varied from 0.1 to 20 nM, based on the potential interference of each enzyme in the phosphorylated peptide detection. The substrate concentrations used were 50 nM or 100 nM depending on the substrate. The substrate concentrations were optimized to obtain acceptable signals and S/B ratios, since it is known that the anti-pTyr antibody can have different affinities for various peptides. If substrate concentrations are too high, then non-specific fluorescence is generated due to random proximity of the europium-anti-pTyr antibody and U*Light* dye. The concentration of ATP was 200 µM, and is non-limiting in the kinase reaction. All five substrates were assayed under very similar conditions for each enzyme. Therefore, the S/B value presented for each substrate is a representation of the relative activity of the enzyme for each substrate. For example, ABL gave S/B values of 13 and 11 for polyGT and polyGAT, respectively. However, the other three substrates provided no signal at equivalent enzyme concentration.

PolyGT gave an S/B ratio \> 3 for 77 kinases. Interestingly, SYK, DDR1, EGFR, FGFR1, MUSK, and RET did not show S/B ratios greater than 3, but some minimal activity between an S/B ratio of 1.4 and 2.9 was observed.

PolyGAT gave an S/B ratio \> 3 for 81 kinases. Only ROR1 and ROR2 did not work with polyGAT, although S/B ratios of 3.4 and 4.2 were observed with polyGT for these two enzymes.

The CDK1 peptide was a very good substrate for two PTK families: Eph and Src. Only the EphA2, A6 and A7 enzymes showed minimal activity out of the 12 EPH enzymes tested. All of the Src family kinases tested had significant activity with the CDK1 peptide.

For the IRS1 peptide, 32 kinases, from 14 families, had an S/B ratio \> 3. Only two of these families (6 kinases) were of the cytoplasmic or non-receptor type: Jak and Fes.

For the JAK1 peptide, 50 kinases, from 19 families, had an S/B ratio \> 3. Some kinases were quite selective for the JAK1 peptide compared to the other four substrates, including EGFR, FLT4, JAK3, KDR, RET, and SYK, where the S/B ratio was at least 3-fold higher than with the other four substrates.

DISCUSSION
==========

In the present work, almost all of the human PTKs were assayed with five peptidic substrates using a TR-FRET technology and purified recombinant enzymes. A unique pattern of human PTK selectivity was observed for the CDK1 and IRS1 peptides, whereas polyGT and polyGAT were substrates for almost all of the kinases and JAK1 was active with over 60% of the kinases. In order to visually demonstrate the selectivity of the peptide substrates, the activity of the PTKs towards the JAK1, CDK1, and IRS1 peptides is illustrated in dendrogram format in Fig. (**[3](#F3){ref-type="fig"}**). In contrast to the JAK1 peptide, where almost all branches are highlighted with active kinases, the CDK1 and IRS1 peptides are only substrates for certain sub-families.

It was clearly observed that, indeed, polyGT and polyGAT can be considered as universal substrates for Tyr kinases and serve as good positive controls for PTK activity. On the other hand, using these non-specific substrates may be a disadvantage, because contaminating Tyr kinases may generate a signal that is not due to the kinase being studied. Polymeric peptides containing acidic amino acids and Tyr were originally described about 25 years ago \[[@R9]\]. To our knowledge, this is the first time that these polymeric peptides have been tested with such a wide variety of Tyr kinases.

Interestingly, the JAK1 peptide seemed to be promiscuous for many Tyr kinases and it also represented a better substrate than polyGT and polyGAT in some cases. This broad activity may be related to the fact that it contains three acidic residues proximal to the Tyr residues: **E**T**D**K**E**YY. As for the polyGT and polyGAT polymers, the presence of acidic amino acids may cause the JAK1 peptide to be a non-specific substrate for Tyr kinases. The lack of specificity towards the JAK1 peptide may also be a caution in other studies of peptide substrate specificity of PTKs. PTK binding to acidic peptides may be unrelated to the specificity of the kinase, but to a general structural preference of all the PTKs.

In the current study, all Src family kinases efficiently utilized the CDK1 peptide as a substrate and further demonstrates the overall preference of the Src family for the CDK1 peptide \[[@R5]\]. Interestingly, two of the three members of the Src-related Frk family, BRK and FRK, do not phosphorylate the CDK1 peptide, although both phosphorylated polyGT and polyGAT. Although the Frk family of kinases has sequence homology to the Src family, the catalytic specificities of the two families are different, further demonstrating the distinct nature of the Frk family of kinases \[[@R12]\].

The ability of almost all Eph kinases to phosphorylate the CDK1 peptide was not predicted. A single report implicating EphA5 as a putative kinase phosphorylating CDK5 Tyr15 has been published \[[@R13]\], and the preference of the Eph family towards this substrate was not revealed by previous studies using synthetic peptides against the EphA3 and EphA4 kinases \[[@R14],[@R15]\]. However, the sequence around Tyr15 in CDK5, KIGEGTYGTVFK, is very similar to the CDK1 peptide in this study: KIGEGTYGVVYK. This is the first time that the Eph family has been shown to directly phosphorylate the CDK-1 (Tyr-15) sequence. The Eph family of receptors is of particular importance due to their role in communication between adjacent cells and there are strong efforts to understand the complex signaling mechanisms of these PTKs \[[@R16]\].

In the current study, 26 of the 32 kinases found to be active against the IRS1 peptide were receptor Tyr kinases, demonstrating that the IRS1 peptide is greatly favored by receptor Tyr kinases. Also, the IRS1 peptide was a very good substrate for JAK-1, 2, and 3 kinases, which are cytoplasmic kinases. The activity of the JAK kinases towards IRS1 has been previously reported \[[@R17]\]. Moreover, Jak family kinases show more sequence homology to receptor Tyr kinases than to cytoplasmic Tyr kinases. Indeed, the kinases acting on the IRS1 peptide tend to group entirely on the left side of the dendrogram shown in Fig. (**[3](#F3){ref-type="fig"}**).

Overall, a high-throughput assay technology was used to profile five Tyr kinase substrates. The CDK1 and IRS1 peptides demonstrated high selectivity for certain subfamilies, whereas the JAK1 peptide is promiscuous. Furthermore, this is the first publication showing the specificity of the Eph family towards the CDK1 (Tyr-15) sequence. Researchers may refer to this study to identify possible substrates for their kinase(s) of interest or to set-up kinase assays to further study the structure and function of the PTK(s).
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polyGT

:    = polyGlu:Tyr(4:1)

polyGAT

:    = polyGlu:Ala:Tyr(1:1:1)

pTyr

:    = phosphorylated tyrosine

PTK

:    = protein tyrosine kinase

S/B

:    = signal to background

TR-FRET

:    = time-resolved fluorescence resonance energy transfer

![In these kinase assays, the binding of a Eu-labeled anti-phospho- Tyr antibody (Eu-Ab) to the phosphorylated U*Light*-labeled substrate brings donor and acceptor molecules into close proximity. After irradiation of the kinase reaction at 320 or 340 nm, the energy from the Eu donor is transferred to the U*Light* acceptor dye which, in turn, generates light at 665 nm. The intensity of the light emission is proportional to the level of U*Light*-substrate phosphorylation.](TOCHGENJ-5-115_F1){#F1}

![The competition curve for JAK2 kinase was performed according to Materials and Methods. The fluorescence signal was plotted versus the concentration of enzyme and the highest concentration of enzyme providing minimal or no interference of signal was chosen for determination of activity versus the various U*Light*-substrates. In this case, 1 nM kinase was chosen. The error bars represent the standard deviation of triplicate measurements.](TOCHGENJ-5-115_F2){#F2}

![Kinases with S/B ratios greater than 3 are highlighted. The names of the kinases not tested were faded out. Dendrogram illustration reproduced courtesy of Cell Signaling Technology, Inc. ([www.cellsignal.com](www.cellsignal.com)).](TOCHGENJ-5-115_F3){#F3}

###### 

Profiling Data for all Kinases.

###### 

A

  Family   Kinase                 Kinase concentration (nM)   polyGT   polyGAT   CDK1   IRS1   JAK1
  -------- ---------------------- --------------------------- -------- --------- ------ ------ ------
  ABL      ABL                    0.25                        13.1     11.1      1.3    1.1    1.2
  ABL      ABL \[T315I\] (ABL1)   0.5                         6.6      6.4       1.3    1.2    1.3
  ACK      ACK                    20                          27.3     27.2      4.8    1.5    2.0
  ABL      ARG                    0.5                         13.2     12.7      1.4    1.2    1.4
  SRC      BLK                    0.5                         16.5     7.8       9.6    1.1    2.6
  TEC      BMX                    0.5                         13.2     9.0       2.2    1.1    1.2
  FRK      BRK                    3                           17.4     3.0       1.4    1.3    1.1
  TEC      BTK                    0.25                        11.8     19.6      3.1    1.0    1.5
  CSK      CSK                    20                          10.4     20.3      1.7    1.3    3.9
  CSK      CTK                    20                          12.6     18.8      1.0    1.0    1.0
  FAK      FAK                    3                           20       13        1.0    1.0    1.0
  FES      FER                    0.25                        12.9     17.1      16.1   9.1    5.8
  FES      FES                    1                           17.1     19        10.3   7.2    4.0
  SRC      FGR                    0.1                         25.1     17.7      4.1    1.1    3.2
  FRK      FRK                    0.5                         20.8     22.9      1.3    1.1    2.2
  SRC      FYN                    0.25                        12.8     10.4      19.7   1.0    2.3
  SRC      HCK                    0.25                        21.3     13.2      12.8   1.2    5.1
  TEC      ITK                    0.5                         9.8      8.5       2.5    1.6    1.6
  JAK      JAK1                   7                           17.6     16.4      1.3    3.7    19.5
  JAK      JAK2                   1                           8.9      7.9       7.2    21.4   41.8
  JAK      JAK3                   0.5                         6.7      6.9       1.3    6.0    37.3
  SRC      LCK                    0.5                         10.4     16.5      6.1    1.0    1.7
  SRC      LYNa                   0.5                         15.6     8.9       14.3   1.1    7.4
  SRC      LYNb                   1                           18.6     13.2      24     1.2    18.3
  FAK      PYK2                   0.25                        15.5     7.7       2.3    1.1    1.3
  SRC      SRC                    0.5                         15.1     18.4      16.6   1.1    5.9
  FRK      SRM                    0.5                         18.3     20.1      8.0    1.3    2.0
  SYK      SYK                    0.5                         2.3      4.1       1.2    1.8    20
  TEC      TEC                    0.5                         25.4     15.4      2.2    1.0    1.8
  ACK      TNK1                   1                           9.3      15.2      2.4    1.6    1.2
  TEC      TXK                    3                           11       18.9      3.2    1.2    1.3
  JAK      TYK2                   4                           6.2      5.3       1.3    7.3    15.2
  SRC      YES                    0.25                        15.3     14        12.8   1.0    3.0
  SYK      ZAP70                  4                           11.1     15.3      1.1    1.1    6.7

###### 

B

  Family   Kinase           Kinase concentration (nM)   polyGT   polyGAT   CDK1   IRS1   JAK1
  -------- ---------------- --------------------------- -------- --------- ------ ------ ------
  ALK      ALK              4                           9.8      7.2       2.6    16.8   3.9
  AXL      AXL              4                           9.8      5.6       1.5    1.6    1.2
  DDR      DDR1             0.5                         2.0      3.0       1.0    1.1    1.0
  DDR      DDR2             0.5                         4.1      5.1       1.0    4.9    1.0
  EGFR     EGFR             0.5                         1.7      5.0       1.8    2.5    19
  EGFR     EGFR \[T790M\]   0.5                         18.1     10.8      1.1    1.2    3.9
  EPH      EphA1            0.5                         24.1     11.4      3.1    1.2    1.2
  EPH      EphA2            0.25                        12.3     7.1       2.1    1.8    3.9
  EPH      EphA3            0.5                         17.4     8.0       4.4    3.5    3.8
  EPH      EphA4            0.5                         12.6     11.3      6.7    2.4    6.4
  EPH      EphA5            1                           18       21.9      19.2   7.6    21.2
  EPH      EphA6            0.5                         14.2     15.5      1.2    1.1    1.3
  EPH      EphA7            0.5                         22.7     11.1      1.4    1.3    1.5
  EPH      EphA8            0.25                        16.4     7.8       3.1    1.6    5.6
  EPH      EphB1            0.5                         25.1     7.9       14.1   8.4    10.6
  EPH      EphB2            0.25                        27.9     13.2      13.1   3.8    5.7
  EPH      EphB3            0.1                         29       11.2      8.3    2.3    4.0
  EPH      EphB4            0.5                         13.7     4.0       12.6   4.8    12
  FGFR     FGFR1            0.5                         2.9      5.0       1.6    13.5   30.8
  FGFR     FGFR2            0.25                        7.8      11.6      1.6    15.5   33.2
  FGFR     FGFR3            0.25                        16       10.7      1.4    8.1    27.6
  FGFR     FGFR4            3                           9.2      5.6       1.2    3.4    20.8
  VEGFR    FLT1             0.25                        22.2     15.4      1.1    1.9    10
  PDGFR    FLT3             0.1                         20.8     13.2      3.6    4.5    25
  VEGFR    FLT4             0.25                        6.9      6.5       1.8    11.4   36.9
  PDGFR    FMS (CSFR)       0.25                        14.6     6.2       1.2    1.4    6.3
  EGFR     HER2             10                          9.3      8.4       1.1    1.1    1.4
  EGFR     HER4 (ERBB4)     0.1                         25.2     14.4      1.1    1.1    1.5
  INSR     IGF1R            0.25                        21.8     14.6      3.1    15.2   12.8
  INSR     INSR             20                          18.3     25.4      1.1    3.2    1.6
  INSR     IRR              0.5                         21.6     9.1       2.4    15.6   12.7
  VEGFR    KDR              0.25                        8.6      4.3       1.3    5.1    30.8
  PDGFR    KIT              2                           13       21.7      1.0    1.0    3.3
  ALK      LTK              1                           21.3     25.1      2.4    3.9    2.7
  AXL      MER              0.25                        29.2     15.9      9.7    5.6    3.2
  MET      MET              0.5                         17       13.2      4.1    4.5    19.7
  MUSK     MUSK             1                           2.5      10.6      1.8    1.1    3.9
  PDGFR    PDGFRA           0.5                         17.8     10.6      1.3    2.4    9.0
  PDGFR    PDGFRB           0.25                        11.2     12.5      1.6    2.0    3.0
  RET      RET              0.5                         1.4      3.2       1.5    6.9    23.6
  MET      RON              0.25                        27.7     25.7      1.3    4.4    4.9
  ROR      ROR1             20                          3.4      1.5       0.9    1.0    1.0
  ROR      ROR2             20                          4.2      1.4       1.0    0.9    1.0
  ROS      ROS              0.25                        23.8     9         4.4    20.5   7.7
  TIE      TIE2             0.5                         19.3     9.4       1.6    2.1    5.4
  TRK      TRKA (NTRK1)     0.5                         16.3     17.5      5.5    11.8   15.1
  TRK      TRKB (NTRK2)     0.5                         22.9     26.3      7.0    11.1   17
  TRK      TRKC (NTRK3)     0.5                         34.1     22.3      1.1    1.7    1.4
  AXL      TYRO3            0.25                        21.5     9.1       4.7    4.8    2.1

The S/B ratios for each kinase are tabulated. The results are separated based on kinase type: A) Cytoplasmic or non-receptor Tyr kinases and B) Receptor Tyr kinases. The classification correlates with Robinson et al. \[[@R10]\] and Manning *et al*. \[[@R11]\].
